Erasca to Present at the Guggenheim Healthcare Talks 2022 Oncology Day

Rhea-AI Summary

Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company, announced its participation in the Guggenheim Healthcare Talks 2022 Oncology Day. The event, featuring CEO Jonathan E. Lim and CFO David M. Chacko, will take place in a virtual format on February 10, 2022, at 2:30 PM ET. The company will also engage in one-on-one investor meetings. A live webcast will be available at Erasca.com/events, with an archived replay for 30 days afterward. Erasca focuses on therapies for RAS/MAPK pathway-driven cancers.

News Market Reaction – ERAS

+0.45%

+0.45% Session move

In the trading session that priced this news, ERAS gained 0.45%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Guggenheim Healthcare Talks 2022 Oncology Day. Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer, will represent Erasca in a virtual fireside chat beginning at 2:30 PM Eastern Time on Thursday, February 10, 2022. The company will also participate in one-on-one investor meetings.

A live webcast of the event will be available online at Erasca.com/events. An archived replay of the event will be available for 30 days following the webcast at Erasca.com/events.

About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of cancer. We have assembled what we believe to be the deepest RAS/MAPK pathway-focused pipeline in the industry. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.

Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com

Source: Erasca, Inc.

FAQ

What is Erasca's participation in the Guggenheim Healthcare Talks 2022?

Erasca will participate in the Guggenheim Healthcare Talks 2022 Oncology Day on February 10, 2022, featuring CEO Jonathan E. Lim and CFO David M. Chacko.

When is the Erasca event at Guggenheim Healthcare Talks 2022?

The event will take place on February 10, 2022, at 2:30 PM Eastern Time.

How can I watch the Erasca presentation during the Oncology Day?

A live webcast of the event can be viewed at Erasca.com/events.

Is an archived version of the Erasca event available?

Yes, an archived replay of the event will be available for 30 days following the live webcast.

What is Erasca's focus in oncology?

Erasca is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.